高剂量伊维菌素联合双氢青蒿素-哌喹在肯尼亚无并发症疟疾成人中的安全性与灭蚊效果(IVERMAL):一项随机、双盲、安慰剂对照试验
在肯尼亚基苏木开展随机双盲安慰剂对照优效试验,141例无并发症恶性疟成人随机接受3天伊维菌素600 μg/kg/天、300 μg/kg/天或安慰剂,均联用双氢青蒿素-哌喹。两种剂量均耐受良好,且使治疗后至少28天内蚊虫存活率降低;300 μg/kg/天在疗效与耐受性间取得较好平衡,作者认为该药有望成为疟疾消除的新工具。
要点
- 伊维菌素600与300 μg/kg/天组蚊虫14天累积死亡率均高于安慰剂组。
- 治疗后28天蚊虫死亡率仍显著升高,两种剂量均优于安慰剂。
- 治疗相关不良事件:600 μg/kg组5/45例(11%),300 μg/kg组2/48例(4%),安慰剂组0/46例。
核心结论
- 两种剂量的伊维菌素均耐受良好,并使治疗后至少28天内蚊虫存活率降低。
- 伊维菌素300 μg/kg/天连用3天在疗效与耐受性之间取得较好平衡,作者认为该药有望成为疟疾消除的潜在新工具。
研究设计与样本
- 在肯尼亚基苏木Jaramogi Oginga Odinga教学与转诊医院开展的随机、双盲、安慰剂对照、优效性试验。
- 纳入18-50岁确诊有症状无并发症恶性疟且同意随访的成人,按性别和体重指数分层,以1:1:1随机分配接受3天伊维菌素600 μg/kg/天、300 μg/kg/天或安慰剂,均联用3天双氢青蒿素-哌喹。
- 2015年7月20日至2016年5月7日评估741例疟疾成人,141例随机分配:600 μg/kg/天组47例、300 μg/kg/天组48例、安慰剂组46例;128例(91%)完成治疗后7天主要结局访视。
- 主要结局为治疗后7天采血喂养的蚊虫14天累积死亡率,分析纳入至少接受一剂研究药物的参与者。
主要发现
- 与安慰剂相比,治疗后7天采血喂养的蚊虫14天死亡风险:伊维菌素600 μg/kg/天组RR 2.26(95%CI 1.93-2.65,p<0.0001),HR 6.32(95%CI 4.61-8.67,p<0.0001)。
- 与安慰剂相比,治疗后7天采血喂养的蚊虫14天死亡风险:伊维菌素300 μg/kg/天组RR 2.18(95%CI 1.86-2.57,p<0.0001),HR 4.21(95%CI 3.06-5.79,p<0.0001)。
- 治疗后28天蚊虫死亡率仍显著升高:伊维菌素600 μg/kg/天组RR 1.23(95%CI 1.01-1.50,p=0.0374),300 μg/kg/天组RR 1.21(95%CI 1.01-1.44,p=0.0337)。
- 治疗相关不良事件:伊维菌素600 μg/kg/天组5/45例(11%),300 μg/kg/天组2/48例(4%),安慰剂组0/46例。
临床怎么用
- 原文结论指出伊维菌素300 μg/kg/天连用3天在疗效与耐受性之间取得较好平衡,该药有望成为疟疾消除的潜在新工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ivermectin is being considered for mass drug administration for malaria due to its ability to kill mosquitoes feeding on recently treated individuals. However, standard, single doses of 150-200 μg/kg used for onchocerciasis and lymphatic filariasis have a short-lived mosquitocidal effect (<7 days). Because ivermectin is well tolerated up to 2000 μg/kg, we aimed to establish the safety, tolerability, and mosquitocidal efficacy of 3 day courses of high-dose ivermectin, co-administered with a standard malaria treatment. METHODS: We did a randomised, double-blind, placebo-controlled, superiority trial at the Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu, Kenya). Adults (aged 18-50 years) were eligible if they had confirmed symptomatic uncomplicated Plasmodium falciparum malaria and agreed to the follow-up schedule. Participants were randomly assigned (1:1:1) using sealed envelopes, stratified by sex and body-mass index (men: <21 vs ≥21 kg/m2; women: <23 vs ≥23 kg/m2), with permuted blocks of three, to receive 3 days of ivermectin 300 μg/kg per day, ivermectin 600 μg/kg per day, or placebo, all co-administered with 3 days of dihydroartemisinin-piperaquine. Blood of patients taken on post-treatment days 0, 2 + 4 h, 7, 10, 14, 21, and 28 was fed to laboratory-reared Anopheles gambiae sensu stricto mosquitoes, and mosquito survival was assessed daily for 28 days after feeding. The primary outcome was 14-day cumulative mortality of mosquitoes fed 7 days after ivermectin treatment (from participants who received at least one dose of study medication). The study is registered with ClinicalTrials.gov, number NCT02511353. FINDINGS: Between July 20, 2015, and May 7, 2016, 741 adults with malaria were assessed for eligibility, of whom 141 were randomly assigned to receive ivermectin 600 μg/kg per day (n=47), ivermectin 300 μg/kg per day (n=48), or placebo (n=46). 128 patients (91%) attended the primary outcome visit 7 days post treatment. Compared with placebo, ivermectin was associated with higher 14 day post-feeding mosquito mortality when fed on blood taken 7 days post treatment (ivermectin 600 μg/kg per day risk ratio [RR] 2·26, 95% CI 1·93-2·65, p<0·0001; hazard ratio [HR] 6·32, 4·61-8·67, p<0·0001; ivermectin 300 μg/kg per day RR 2·18, 1·86-2·57, p<0·0001; HR 4·21, 3·06-5·79, p<0·0001). Mosquito mortality remained significantly increased 28 days post treatment (ivermectin 600 μg/kg per day RR 1·23, 1·01-1·50, p=0·0374; and ivermectin 300 μg/kg per day 1·21, 1·01-1·44, p=0·0337). Five (11%) of 45 patients receiving ivermectin 600 μg/kg per day, two (4%) of 48 patients receiving ivermectin 300 μg/kg per day, and none of 46 patients receiving placebo had one or more treatment-related adverse events. INTERPRETATION: Ivermectin at both doses assessed was well tolerated and reduced mosquito survival for at least 28 days after treatment. Ivermectin 300 μg/kg per day for 3 days provided a good balance between efficacy and tolerability, and this drug shows promise as a potential new tool for malaria elimination. FUNDING: Malaria Eradication Scientific Alliance (MESA) and US Centers for Disease Control and Prevention (CDC).
引用
- Smit MR, Ochomo EO, Aljayyoussi G, et al. Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2018. PMID: 29602751. doi:10.1016/S1473-3099(18)30163-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。